*Sponsored
Jeff Ackerman Initiates Coverage On (Nasdaq: INBS) Starting This Morning
—Thursday, October 30, 2025
Be First To See What's Next For (INBS) — Get The Full Details
Delivered Right To Your Mobile Device.
(INBS) Comes Backed By Several Potential Catalysts—But Here's
What We Can Tell You Right Now:
Small Float: With Fewer Than 9M Shares Available To The Public, (INBS)'s Small Float Could Have The Potential For Big Moves If Demand Begins To Shift.
Under The Radar: Around $1 This Week, (INBS) Remains Largely Unnoticed By Broader Market Participants At Current Levels.
Analyst Spotlight: Jeffrey S. Cohen Of Ladenburg Thalmann Set A $12 Target On (INBS), Which Suggets 1,100% Upside From Recent Levels.
Pull Up (INBS) Before The Bell Rings…
October 30, 2025
10 Minutes To Go | See Why (Nasdaq: INBS) is Topping Our Watchlist Right Now Dear Reader, Have you pulled up (INBS) yet? There's less than 10 minutes to go before the bell rings. Every so often, a quiet breakthrough begins to shift an entire industry — not with hype, but with execution. While others chase the next big concept, a small group of innovators focuses on real-world transformation, measured one test, one result, one life at a time. And right now, a company in New York may be rewriting the future of workplace and clinical screening with a device that fits in the palm of your hand. That company is Intelligent Bio Solutions Inc. (Nasdaq: INBS) — and it's topping our watchlist this morning, Thursday, October 30, 2025, as momentum builds around its expanding commercial footprint and upcoming U.S. regulatory milestones. According to MarketWatch, (INBS) has fewer than 9M shares available in its public float. When floats are this small, there's the potential for big moves if demand begins to shift. Currently trending around $1 this week, (INBS) appears to be flying under the radar and remains in what many would call a discovery phase for most readers. Just yesterday, Jeffrey S. Cohen, an analyst with Ladenburg Thalmann & Co. Inc., published a new report setting a $12 target on (INBS) — which suggests 1,100% upside potential from its recent range. 
Momentum like this doesn't come out of nowhere. Behind it is a technology that's already transforming workplace safety, logistics, and healthcare testing across multiple continents. With enterprise adoption accelerating and a U.S. entry now on the horizon, (INBS) appears to be entering a new phase of visibility among advanced screening technologies. A Company Redefining What "Non-Invasive" Really Means
(INBS) is a medical technology company delivering intelligent, rapid, and pain-free testing solutions designed to make drug and diagnostic screening faster, cleaner, and more humane. Its flagship innovation — the Intelligent Fingerprinting Drug Screening System — replaces traditional urine or saliva testing with a simple fingerprint-based process that collects a sweat sample in seconds and delivers results in under ten minutes. By reading metabolites in fingerprint sweat, this technology eliminates biohazard risk, removes the need for gender-specific collection, and allows on-site testing virtually anywhere — from factory floors to airports, construction zones, and even roadside safety checks. 
The result: a faster, cleaner, and more dignified experience for both employers and employees. Razor-Blade Model — Real Growth Behind the Innovation
In July 2025, (INBS) recorded its highest-ever monthly cartridge sales — over 12,500 units — a 60 percent year-on-year increase.
These cartridges — the consumable heart of its fingerprint testing system — sit at the center of the company's razor/razor-blade business model, generating recurring revenue each time a reader is used in the field. CEO Harry Simeonidis called it "a clear validation of our installed base and our ability to scale recurring consumable demand." That momentum continues as the company wins larger multi-site contracts across transportation and logistics, creating a foundation for sustained growth as new deployments roll out globally. Expanding Enterprise Adoption — From Construction to Nuclear Sectors
On October 23, 2025, (INBS) announced one of its most significant UK commercial wins to date — a major contract with a multinational industrial service provider employing 3,000 people across the UK and Ireland and 30,000 globally. This deployment replaces slow, third-party urine testing with (INBS)'s rapid fingerprint-based system — reducing downtime, increasing efficiency, and modernizing compliance processes across safety-critical environments like energy, defense, and nuclear operations. Customer feedback described the switch not as if but when and how, reinforcing how deeply (INBS)'s technology aligns with operational and cultural priorities inside large organizations. It's part of a larger wave of enterprise adoption across transportation, mining, and construction, driving expanding recurring cartridge sales and new international visibility for the brand. Toward U.S. FDA Clearance
(INBS)'s progress isn't limited to commercial growth. The company continues to advance its FDA 510(k) clearance process for U.S. market entry beyond the "Forensic Use Only" category. After responding to an extensive Additional Information (AI) request earlier this year, the company initiated new clinical studies designed to strengthen its updated submission and now anticipates FDA clearance in the second half of 2026.
As Vice President of Product Development Peter Passaris noted, "We have a clear and achievable timeline … the additional data will strengthen our package."
Meanwhile, global operations continue to grow — over 480 active accounts across 24 countries, supported by 18 distribution partners — underscoring a robust international base that keeps momentum strong while the U.S. pathway advances. The Bigger Picture — A Technology Built for Modern Workforces
Across the U.S., drug misuse costs employers over $400B each year in productivity loss and safety incidents. (INBS)'s system addresses this reality by offering: - Rapid detection of recent use (within 16–24 hours), identifying current impairment rather than historical exposure.
- Non-invasive testing that preserves dignity and removes the need for specialized collection environments.
- Portable scalability, allowing large organizations to perform batch testing across multiple sites simultaneously.
These capabilities make fingerprint-based analysis not just an alternative, but a potential new standard for modern safety-critical industries. Looking Ahead
With record cartridge sales, a growing roster of global enterprise clients, and clear visibility toward U.S. FDA clearance, (INBS) appears positioned to enter 2026 with significant momentum. Its dual-engine strategy — expanding commercial operations globally while advancing regulatory milestones — sets a foundation for both near-term scalability and long-term technological leadership. As the world demands faster, smarter, and more humane screening systems, (INBS) stands at the intersection of innovation and necessity. 7 Reasons Why (HCTI) Just Hit Our Radar This Morning
—Thursday, October 30, 2025 1. Small Float: With fewer than 9M shares listed as available, (INBS)'s small float could have the potential for big moves if demand begins to shift. 2. Analyst Spotlight: A recent report from Jeffrey S. Cohen at Ladenburg Thalmann & Co. Inc. placed a $12 target on (INBS) — which suggests an approximate 1,100% upside potential from its recent trading range. 3. Record Growth: (INBS) recently reported all-time-high cartridge sales exceeding 12,500 units — reflecting 60% year-over-year growth in recurring consumable demand. 4. Expanding Global Reach: Now active in 24 countries with more than 480 accounts and 18 distribution partners, (INBS) continues broadening its commercial footprint. 5. Regulatory Progress: After advancing its FDA 510(k) submission process, (INBS) anticipates potential clearance for U.S. market entry in the second half of 2026. 6. Enterprise Momentum: A new contract announced in October 2025 with a multinational industrial group employing 30,000 staff underscores growing large-scale adoption of (INBS)'s technology. 7. Under-the-Radar: Currently trending around $1 this week, (INBS) remains largely undiscovered by broader market participants — a level often associated with early-phase visibility shifts. Pull Up (INBS) Before The Bell Rings…
When you line up all seven reasons, a clear picture begins to emerge. (INBS) has a small float, analyst attention, accelerating commercial momentum, and a clear path toward regulatory progress — all supported by measurable milestones and expanding global reach. Each of these factors makes (INBS) a name worth watching closely this morning. We have all eyes on (INBS) right now. Take a look at (INBS) this morning before the bell rings. Also, keep a look out for my next update — it could be here any moment. Sincerely,
Jeff Ackerman
Managing Editor
Stock News Trends | 
0 Response to "10 Minutes To Go: See Why (Nasdaq: INBS) is Topping Our Watchlist Right Now"
Post a Comment